Last reviewed · How we verify
NCT04368819: ARAMIS
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
Phase 2, PHASE3 trial testing Allopurinol 300 MG in Refractory Angina in 40 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | Ministry of Health, Brazil |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 3 March 2021 |
| Primary completion | 30 September 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Allopurinol 300 MG — full drug profile →
- Placebo oral tablet — full drug profile →
Conditions studied
- Refractory Angina — all drugs for Refractory Angina →
Sponsor
Ministry of Health, Brazil
Who can join
18 and older, any sex, with Refractory Angina. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite numerous advances in medical treatment and revascularization procedures for the treatment of patients with stable angina, debilitating symptoms that are unresponsive to conventional therapy may occur in patients unsuitable for revascularization, a condition known as refractory angina. Allopurinol, a methylxanthine oxidase inhibitor, is widely used in the treatment of gout and asymptomatic hyperuricemia. On the other hand, the anti-ischemic effects of allopurinol have been the subject of increasing interest. Therefore, the investigators will study the safety and efficacy of allopurinol in alleviating ischemic symptoms in patients with refractory angina already on optimal medical therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04368819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Allopurinol 300 MG
Trials testing the same drug.
- NCT05805605 — Allo HSCT Using RIC and PTCy for Hematological Diseases · Phase 2 · recruiting
- NCT05511766 — Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis · Phase 2, PHASE3 · unknown
- NCT05545670 — Allopurinol to Prevent Cirrhosis Related Morbidities · Phase 2, PHASE3 · completed
- NCT04052932 — A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout · Phase 3 · completed
Other recruiting trials for Refractory Angina
Currently open trials in the same condition.
- NCT07048808 — Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. · Phase 2 · recruiting
- NCT05711849 — Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina · Phase 2 · recruiting
- NCT05492110 — Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microva · NA · recruiting
- NCT04606459 — COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina · NA · recruiting
- NCT01566175 — Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina · NA · recruiting
Other Ministry of Health, Brazil trials
Trials by the same sponsor.
- NCT06464276 — Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD S · completed
- NCT04760821 — Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19 · Phase 2 · unknown
- NCT00350766 — Cell Therapy in Myocardial Infarction · Phase 2, PHASE3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04368819 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ministry of Health, Brazil
- Last refreshed: 24 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04368819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing